Healthcare & Medical Devices Global On demand · 24-48h

Global Syringe Market Strategic Research Report

Global Syringe Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Syringe Market
$10.99B2025
3.5%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Conventional Syringe, Safety Syringe

By Application: Medical, Non-medical

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: BD, Embecta, Terumo, Weigao Medical, Cardinal Health, Nipro, B.Braun, ICU Medical, Kandlai, Double Pigeon Group, Bridge Group, Feel Tech, Jiangsu Zhengkang Medical, Shuguang Huizhikang, Jiangsu Jichun Medical Equipment, Sanxin Medical, Shengguang Group, Hongda Medical, Anhui Hongyu Wuzhou, Caina Medical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 144 pages
Market size 2025
$10.99B
Billion USD
Forecast CAGR
3.5%
2025-2032
Forecast 2032
$14B
Projected
Regiões
5
Asia Pacific · Latin America · MEA · Europe · North America

Visão geral

Scope of the Report

The global Syringe market size is predicted to grow from US$ 10,990 million in 2025 to US$ 13,930 million in 2032; it is expected to grow at a CAGR of 3.5% from 2026 to 2032.

A syringe is a medical device used for administering drugs or extracting body fluids, widely applied in vaccination, drug infusion, clinical blood sampling, and laboratory operations. Standard syringes consist of a needle, barrel, plunger, and safety protection mechanisms, emphasizing sterility, single-use, and ease of operation to minimize infection and cross-contamination risks. As healthcare services extend to primary care and community settings, innovative products such as prefilled syringes, auto-retractable syringes, and micro-injection devices are increasingly adopted, balancing safety, patient comfort, and precise dosage control. Leading manufacturers globally optimize costs through smart manufacturing and large-scale operations, while adhering to ISO, FDA, and national medical device regulations, ensuring product reliability and compliance in high-intensity usage scenarios. Technological upgrades and product iterations in the syringe industry directly support vaccination, chronic disease management, and in vitro diagnostics, underpinning rapid market expansion and providing foundational support to global healthcare systems.In 2024, global syringe production reached approximately 84.12 billion units, with an average global market price of around US$ 122.9 per k unit.

The global syringe market is driven by rising vaccination volumes, expanding chronic disease management needs, and public healthcare system development. COVID-19 vaccination campaigns and seasonal influenza vaccination programs have created long-term, inelastic demand through government procurement and public health initiatives, stimulating capacity expansion and technological innovation. The growing chronic disease patient population, particularly for diabetes, anticoagulation, and biologic drug injections, provides market opportunities for prefilled and smart syringes. Leading international and domestic manufacturers leverage automated production, precision molding, and intelligent inspection to enhance product consistency and safety while reducing unit costs and strengthening competitiveness. Policy support for primary care, telemedicine, and home healthcare further promotes syringe penetration in community and home settings. Global supply chain integration and increasing OEM/ODM collaborations support cross-regional market expansion and capital growth, establishing long-term growth momentum.Despite strong demand, the syringe industry faces multiple challenges. Regulatory compliance is increasingly stringent, requiring substantial investment to meet FDA, CE, and ISO certifications, raising operational costs. The industry is highly fragmented, with intense price competition in the low-end market limiting profit margins, forcing companies to rely on technological innovation and brand building for differentiation. Raw material price volatility, rising logistics costs, and international trade uncertainties increase supply chain risk, particularly during peak vaccination periods and public health emergencies, requiring effective production continuity and inventory management. Additionally, tightening environmental regulations regarding plastic syringe disposal and recycling increase long-term operational costs and risk management challenges.Downstream syringe demand is becoming more diversified, personalized, and high-end. Traditional hospitals and laboratories remain core markets, but rapid growth in home self-management, community healthcare, and telemedicine services is driving adoption of prefilled, micro, and smart syringes. Continuous vaccination campaigns, normalized chronic disease injections, and expansion of in vitro diagnostics jointly support long-term stable demand. Healthcare digitalization integrates syringes with wearable devices, remote monitoring systems, and cloud-based data platforms, enabling closed-loop management and precise dose tracking, improving patient experience and safety. Companies are gradually transforming from single consumable suppliers to comprehensive injection solution providers, unlocking new incremental markets and long-term commercial value.

This report presents a comprehensive overview of the global Syringe market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Conventional Syringe
  • Safety Syringe

Segment by Application

  • Medical
  • Non-medical

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Syringe market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Medical, Non-medical evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Syringe Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 3.5%
Regional growth momentum
Market share by segment
Key metrics
Base value
$10.99B
2025
Forecast
$14B
2032
CAGR
3.5%
2025–2032
Regiões
5
global
Key companies
BDEmbectaTerumoWeigao MedicalCardinal HealthNiproB.BraunICU Medical
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Conventional SyringeSafety Syringe
By Application
MedicalNon-medical

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Conventional Syringe
  • 3.1.3 Safety Syringe
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Medical
  • 4.1.3 Non-medical
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 BD
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Embecta
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Terumo
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Weigao Medical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Cardinal Health
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Nipro
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 B.Braun
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 ICU Medical
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Kandlai
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Double Pigeon Group
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Bridge Group
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Feel Tech
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Jiangsu Zhengkang Medical
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Shuguang Huizhikang
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Jiangsu Jichun Medical Equipment
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Sanxin Medical
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Shengguang Group
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Hongda Medical
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Anhui Hongyu Wuzhou
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Caina Medical
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Syringe market?
The global Syringe market is estimated at US$ 10.99 billion in 2025 (base year) and is projected to reach US$ 13.93 billion by 2032.
How fast is the Syringe market expected to grow?
The market is expected to grow at a CAGR of 3.5% from 2026 to 2032, expanding from US$ 10.99 billion in 2025 to US$ 13.93 billion in 2032, roughly 1.3 times its base-year value.
What does the Syringe market cover?
A syringe is a medical device used for administering drugs or extracting body fluids, widely applied in vaccination, drug infusion, clinical blood sampling, and laboratory operations. Standard syringes consist of a needle, barrel, plunger, and safety protection mechanisms, emphasizing sterility, single-use, and ease of operation to minimize infection and cross-contamination risks.
What are the main segments of the Syringe market by type?
By type, the market is segmented into Conventional Syringe and Safety Syringe.
Which applications drive demand in the Syringe market?
Key applications covered include Medical and Non-medical.
Who are the key players in the Syringe market?
Key players profiled include BD, Embecta, Terumo, Weigao Medical, Cardinal Health, Nipro, B.Braun and ICU Medical, among 20 companies covered in total.
Which regions and countries are covered for Syringe?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Syringe market?
The global syringe market is driven by rising vaccination volumes, expanding chronic disease management needs, and public healthcare system development.
What challenges does the Syringe market face?
Global supply chain integration and increasing OEM/ODM collaborations support cross-regional market expansion and capital growth, establishing long-term growth momentum.Despite strong demand, the syringe industry faces multiple challenges.
Who should buy the Syringe market report?
The report is intended for manufacturers and solution providers, distributors and end users in Medical and Non-medical, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Syringe market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.